Intervention not reported
Self‐controlled case series (hospitalisations) ‐ hospitalisations ‐ risk period: 0 to 60 days · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series (hospitalisations) ‐ hospitalisations ‐… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 0 to 5 days · children 9 months to 15 years old
The intervention may leads to higher self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 0… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 6 to 60 days · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series (GP visits) ‐ GP visit ‐ risk period: 6… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ lobar pneumonia ‐ lobar pneumonia risk period (0 to 90 days) · children 9 months to 15 years old
The intervention may leads to lower self‐controlled case series ‐ lobar pneumonia ‐ lobar pneumonia risk… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ invasive bacterial infections ‐ invasive bacterial infections risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ invasive bacterial infections ‐… (low certainty).
1 finding from 1 review
Total failure: day 28 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
Total failure day 28 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure [day 42 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
1 finding from 1 review
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
1 finding from 1 review
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
Total failure: day 28 (PCR‐adjusted) · children under 5 years of age
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐amodiaquine (low certainty).
1 finding from 1 review
Total failure day 28 PCR‐unadjusted · children under 5 years of age
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐amodiaquine (low certainty).
1 finding from 1 review
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artesunate‐mefloquine (high certainty).
1 finding from 1 review
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐mefloquine (low certainty).
1 finding from 1 review
Total failure: day 28 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
Intervention not reported
Time taken to establish full gavage feeding (days) · intermittent bolus gavage tube feeding of preterm and low birth weight infants
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Intervention not reported
Feeding intolerance (number of episodes per day) · intermittent bolus gavage tube feeding of preterm and low birth weight infants
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Length of hospital stay · preterm infants
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ stoma formation (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ stoma… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review